Drugs / GBM6-AD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02549833 | Oct 2016 → Aug 2022 | astrocytic tumor, oligoastrocytoma, oligodendroglioma | Jennie Taylor | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06305910 Background | Mar 2024 → Sep 2025 overdue | diffuse midline glioma, H3 K27M-mutant | OX2 Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GBM6-AD | “fixed doses of 1mg GBM6-AD vaccine” NCT06305910 ↗ |
| Modality | Vaccine | “vaccination with GBM6-AD, lysate of an allogeneic glioblastoma stem cell line” PMID 34882581 ↗ Feb 2022 |
| Route | Subcutaneous | “Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination” NCT02549833 ↗ |